Max Healthcare

About: Max Healthcare is a healthcare organization based out in New Delhi, India. It is known for research contribution in the topics: Population & Medicine. The organization has 391 authors who have published 410 publications receiving 14404 citations.

A big disparity between the demand and supply of hand surgeons in India.

Abstract: The editorial board of Journal of Clinical Orthopedics and Trauma (JCOT), have decided to bring out a special issue focused on the ailments of hand and wrist, so as to increase an awareness among orthopedic surgeons. Despite a large number of qualified orthopaedic surgeons (around 20,000), there are only a handful of hand and wrist specialists available. In the United States of America there are 0.6 hand surgeons per 100,000 populations.1 Although, we do not have accurate figures for India but we can assume these to be lesser than 1/10th compared to the USA. The Indian Society of Surgery for Hand has only 700 registered members, for a population of 1.4 billion people. There is a huge burden or traumatic injuries of the hand, in India. These accidental injuries not only lead to dysfunction and permanent hand deformities but also cause severe financial losses due to absence from the work.1 Occupational hand injuries are the most commonly encountered injuries in young males. Hence, not only the management of these complex injuries should be undertaken promptly by a hand specialist, but also an emphasis needs to put in place about the prevention of these injuries at the workplace, by education and improving the environment around the workers.2,3 Hence, there is a huge demand and need for the orthopaedic surgeons, specializing in the hand and wrist surgery in India, since we face a massive challenge in dealing with these traumatic injuries, congenital and acquired deformities and until recently these were either neglected willfully or were not treated adequately by the surgeons in India. This special issue on Hand and wrist encompasses a variety of review and research papers and some interesting case reports, on a variety of common and rarer problems involving the hand and wrist. A comprehensive review for the management of crush injuries of hand has been provided by et al.4 Neglected and chronic scaphoid fractures with and without associated inter-carpal ligament injuries are challenging to manage. Garg et al.5 and Singh et al.6 have given a comprehensive review on the management of these injuries. Peripheral nerve injuries of the upper limb and brachial plexus lead to paralysis of muscles controlling the hand. The research articles by Agarwal et al.7,8 have discussed the management of radial nerve palsy by various tendon transfers and Dhal et al.9 have presented their experience of tendon transfers in medial nerve palsy. Flexor tendon injuries of the hand are serious in nature. These must be treated in time and meticulously by surgical repair, other it becomes challenging to manage these later on. Agarwal et al.10 have presented their experience of using an oOrdinary PVC feeding tube, as a low-cost alternative to silicon rod, for staged flexor tendon reconstruction in zone II of hand. Et al.,11 from Iraq, have shared their experience of the repair of Flexor Tendon Injuries by Four Strands Cruciate Technique Versus Two strands Kessler Technique.

Pediatric & Neonatal Mechanical Ventilation

Abstract: Pediatric and neonatal mechanical ventilation , Pediatric and neonatal mechanical ventilation , کتابخانه دیجیتالی دانشگاه علوم پزشکی و خدمات درمانی شهید بهشتی

Oncology Gold Standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.

Abstract: We present the 2017 Oncology Gold Standard Practical Consensus Recommendation for use of monoclonal antibodies in the management of advanced squamous cell carcinoma of head neck region.

To study the maternal and fetal outcome in obese -pregnant mothers compared with non-obese pregnant mothers in an urban population.

Abstract: The objective of this study was to assess the maternal and fetal outcome in obese mothers (body mass index (BMI) >27.5 kg/m2) compared with non-obese mothers (BMI <27.5 kg/m2) and to observe the persistence of abnormalities in mother and newborn for 6 weeks post-partum. This was a prospective case–control study comprising pregnant women attending the …

Cardiotoxicity in patients on trastuzumab in HER2-positive breast cancer – A retrospective analysis from a center in North India

Abstract: Objectives: Cardiotoxicity has been associated with trastuzumab for long and its relation with anthracyclines has also been well established. The study aims to assess the cardiotoxicity in patients on trastuzumab in human epidermal growth receptor 2-positive breast cancer. Material and Methods: This retrospective study consisting of a 3 years database of 112 patients with breast cancer from a tertiary care center in India. A total of 64 patients were scrutinized meeting the eligibility criteria. The primary eligibility criteria were availability of baseline, 3 monthly, end of treatment, and 3 months post-treatment left ventricular ejection fraction (LVEF) profile data. Results: 41/62 patients (66.1%) showed decrease in the LVEF profiles having mean reduction of 6%. Of these 41 patients, 34 (53.1%) patients exhibited a drop of 0–5%, 4 (6.2%) showed a drop of 6–10%, and 3 (4.6%) patients showed a drop of more than 10%. A significant drop (more than 10%) in the LVEF profile was observed in mean time of 6 months (8 cycles) which recovered to baseline value with the median follow-up of 3 months post-cessation of trastuzumab. Most of patients in the LVEF drop >10% group (70%) had received an anthracyclines based regimen. Conclusion: Our study demonstrated a mean drop of >10% in the LVEF profiles (4.6%) patients after mean follow-up of 6 months after starting therapy with trastuzumab and reverted back to baseline value after over a mean of 3 months post completing therapy with trastuzumab. This warrants regular and strict surveillance for the first 6 months and thereafter also after starting therapy with trastuzumab.